Akira Hamada, Kenichi Suda, Masaya Nishino, Keiko Obata, Hana Oiki, Tomoyo Fukami, Shota Fukuda, Toshio Fujino, Shuta Ohara, Takamasa Koga, et al. Secondary mutations of the EGFR gene that confer resistance to mobocertinib in EGFR exon 20 insertion. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2023
Toshio Fujino, Kenichi Suda, Takamasa Koga, Akira Hamada, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuya Mitsudomi. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation. Journal of hematology & oncology. 2022. 15. 1. 79-79
Akira Hamada, Kenichi Suda, Toshio Fujino, Masaya Nishino, Shuta Ohara, Takamasa Koga, Takanobu Kabasawa, Masato Chiba, Masaki Shimoji, Makoto Endoh, et al. Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC. JTO clinical and research reports. 2022. 3. 5. 100321-100321
Activity of Tarloxotinib in HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance.
(19th World Conference on Lung Cancer 2019 2019)
Activity of novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance.
(19th World Conference on Lung Cancer 2018)
Can Limited Resection Be Accepted As an Alternative Treatment Option for Patients with Early Stage Small Cell Lung Cancer?
(18th World Conference on Lung Cancer 2017)
Recurrence and Survival Outcome After Segmentectomy for Non-Small Cell Lung Cacner: A Long-term Follow-up Study at Single Institute.
(17th World Conference on Lung Cancer 2016)
